Abbott Laboratories vs. Relmada Therapeutics, Inc. Common Stock
Abbott Laboratories and Relmada Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | RLMD | |
|---|---|---|
| Market Cap | $201.88 billion | $488.55 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | RLMD | |
|---|---|---|
| P/E Ratio | 37.58 | — |
| Price / Book | 3.90 | — |
| Price / Sales | 4.33 | — |
ABT and RLMD split the valuation factors evenly.
Profitability
| ABT | RLMD | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and RLMD split the profitability factors evenly.
Dividend
| ABT | RLMD | |
|---|---|---|
| Dividend Yield | 2.17% | — |
| Payout Ratio | 81.55 | — |
ABT and RLMD split the dividend factors evenly.
Risk & Sentiment
| ABT | RLMD | |
|---|---|---|
| Short Interest | 0.57% | 0.00% |
RLMD leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, RLMD overview, RLMD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.